A-Mansia

A-Mansia is the latest co-spin-off from the University of Louvain (UCL) and Wageningen University. It aims to develop Akkermansia-based products.

[Seventure Partners @SeventureP]

[Heath for Life Capital I ™ annual conference] @a_mansia is using next-generation beneficial microbes restoring the gut barrier function. #Aktigut® : the first dietary supplements containing pasteurized A.muciniphila to tackle the root cause of #obesity & #prediabetes

[A-Mansia @a_mansia]

Don’t miss our booth (M93) at Vitafoods 2019! #VFE19 #Vitafoods2019

[GutMicrobiota Health @GMFHx]

'New insights into the role of gut microbiota in rheumatoid arthritis' https://t.co/dfNJL4gUXy

[Seventure Partners @SeventureP]

#Microbiome : En vidéo, une #bactérie attrape de l'ADN https://t.co/R4xJqiS5yW @futurasciences

[BÉNÉFIQ @BENEFIQ_Expo]

Session 9 of @BENEFIQ_Expo on October 3 features Dr. Maria L. Marco, expert in lactic acid bacteria in food systems and as part of the gut microbiome. Presented by @biokplus. @INAF_Qc @universitelaval

[GutMicrobiota Health @GMFHx]

This new open access review presents the MiBioGen consortium as the latest project related to microbiota-genome-wide association studies. With 18 population cohorts & 19,000 subjects it will provide a fuller picture of the human gut microbiome https://t.co/hTeDkBVsu1

[KGK Science @KGKScience]

Our Founder and CEO Najla Guthrie participated as a judge for the NCN Venture Den contest at #Vitafoods2018! Congratulations to the winner A-Mansia! We love seeing new talent in the industry. #VFE2018 @VitafoodsEurope

[A-Mansia @a_mansia]

A-Mansia biotech, a spin-off from Wageningen University in the Netherlands and the University of Louvain in Belgium, has secured €13M in Series A financing. The company will put the funding towards developing its technology, which uses Akkermansia muciniphila, a gut bacterium.

[A-Mansia @a_mansia]

https://t.co/AhEXIY74Lx